170 related articles for article (PubMed ID: 18813828)
1. The growth inhibition of hepatocellular and cholangiocellular carcinoma cells by gemcitabine and the roles of extracellular signal-regulated and checkpoint kinases.
Matsumoto K; Nagahara T; Okano J; Murawaki Y
Oncol Rep; 2008 Oct; 20(4):863-72. PubMed ID: 18813828
[TBL] [Abstract][Full Text] [Related]
2. Gefitinib and gemcitabine coordinately inhibited the proliferation of cholangiocarcinoma cells.
Nakajima Y; Takagi H; Kakizaki S; Horiguchi N; Sato K; Sunaga N; Mori M
Anticancer Res; 2012 Dec; 32(12):5251-62. PubMed ID: 23225424
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of gemcitabine-induced suppression of human cholangiocellular carcinoma cell growth.
Toyota Y; Iwama H; Kato K; Tani J; Katsura A; Miyata M; Fujiwara S; Fujita K; Sakamoto T; Fujimori T; Okura R; Kobayashi K; Tadokoro T; Mimura S; Nomura T; Miyoshi H; Morishita A; Kamada H; Yoneyama H; Okano K; Suzuki Y; Masaki T
Int J Oncol; 2015 Oct; 47(4):1293-302. PubMed ID: 26252371
[TBL] [Abstract][Full Text] [Related]
4. Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine.
Isono M; Hoffmann MJ; Pinkerneil M; Sato A; Michaelis M; Cinatl J; Niegisch G; Schulz WA
J Exp Clin Cancer Res; 2017 Jan; 36(1):1. PubMed ID: 28049532
[TBL] [Abstract][Full Text] [Related]
5. Role of checkpoint kinase 1 in preventing premature mitosis in response to gemcitabine.
Morgan MA; Parsels LA; Parsels JD; Mesiwala AK; Maybaum J; Lawrence TS
Cancer Res; 2005 Aug; 65(15):6835-42. PubMed ID: 16061666
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas.
Kubicka S; Rudolph KL; Tietze MK; Lorenz M; Manns M
Hepatogastroenterology; 2001; 48(39):783-9. PubMed ID: 11462924
[TBL] [Abstract][Full Text] [Related]
7. Anti‑cancer effects of a novel Pan‑RAF inhibitor in a hepatocellular carcinoma cell line.
Wang W; Xu B; Li Q; Jiang D; Yan S
Mol Med Rep; 2018 Apr; 17(4):6185-6193. PubMed ID: 29484394
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells.
Nakagawa S; Sakamoto Y; Okabe H; Hayashi H; Hashimoto D; Yokoyama N; Tokunaga R; Sakamoto K; Kuroki H; Mima K; Beppu T; Baba H
Oncol Rep; 2014 Feb; 31(2):983-8. PubMed ID: 24337160
[TBL] [Abstract][Full Text] [Related]
9. Apoptosis of liver cancer cells by vitamin K2 and enhancement by MEK inhibition.
Matsumoto K; Okano J; Nagahara T; Murawaki Y
Int J Oncol; 2006 Dec; 29(6):1501-8. PubMed ID: 17088989
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
[TBL] [Abstract][Full Text] [Related]
11. Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer.
Rizell M; Andersson M; Cahlin C; Hafström L; Olausson M; Lindnér P
Int J Clin Oncol; 2008 Feb; 13(1):66-70. PubMed ID: 18307022
[TBL] [Abstract][Full Text] [Related]
12. Cholangiocarcinoma cell line TK may be useful for the pharmacokinetic study of the chemotherapeutic agent gemcitabine.
Kamada M; Akiyoshi K; Akiyama N; Funamizu N; Watanabe M; Fujioka K; Ikeda K; Manome Y
Oncol Rep; 2014 Aug; 32(2):829-34. PubMed ID: 24891233
[TBL] [Abstract][Full Text] [Related]
13. Survival pathway of cholangiocarcinoma via AKT/mTOR signaling to escape RAF/MEK/ERK pathway inhibition by sorafenib.
Yokoi K; Kobayashi A; Motoyama H; Kitazawa M; Shimizu A; Notake T; Yokoyama T; Matsumura T; Takeoka M; Miyagawa SI
Oncol Rep; 2018 Feb; 39(2):843-850. PubMed ID: 29251327
[TBL] [Abstract][Full Text] [Related]
14. CHK1 and CHK2 are differentially involved in mismatch repair-mediated 6-thioguanine-induced cell cycle checkpoint responses.
Yan T; Desai AB; Jacobberger JW; Sramkoski RM; Loh T; Kinsella TJ
Mol Cancer Ther; 2004 Sep; 3(9):1147-57. PubMed ID: 15367709
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine.
Yokoi K; Fidler IJ
Clin Cancer Res; 2004 Apr; 10(7):2299-306. PubMed ID: 15073105
[TBL] [Abstract][Full Text] [Related]
16. Survivin-mediated therapeutic efficacy of gemcitabine through glucose-regulated protein 78 in hepatocellular carcinoma.
Hung CS; Lin SF; Liu HH; Kuo LJ; Li LT; Su HY; Liew PL; Lin FY; Wei PL; Liu DZ; Chang YJ
Ann Surg Oncol; 2012 Aug; 19(8):2744-52. PubMed ID: 22258814
[TBL] [Abstract][Full Text] [Related]
17. [Effectiveness of systemic chemotherapy of GEM+CBDCA+5-FU/LV and hepatic arterial infusion of CDDP in a case of advanced, combined hepatocellular-cholangiocarcinoma with multiple lung metastases].
Tani S; Murata S; Tamura M; Fukunaga K; Morita M; Hirata Y; Iida H; Kakuno A; Nishigami T; Yamanaka N
Nihon Shokakibyo Gakkai Zasshi; 2011 Nov; 108(11):1892-901. PubMed ID: 22056711
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of FGFR2 enhances chemosensitivity to gemcitabine in cholangiocarcinoma through the AKT/mTOR and EMT signaling pathways.
Jaidee R; Kukongviriyapan V; Senggunprai L; Prawan A; Jusakul A; Laphanuwat P; Kongpetch S
Life Sci; 2022 May; 296():120427. PubMed ID: 35218764
[TBL] [Abstract][Full Text] [Related]
19. Adenovirus type 5 E1A sensitizes hepatocellular carcinoma cells to gemcitabine.
Lee WP; Tai DI; Tsai SL; Yeh CT; Chao Y; Lee SD; Hung MC
Cancer Res; 2003 Oct; 63(19):6229-36. PubMed ID: 14559808
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of checkpoint kinase 1 potentiates anticancer activity of gemcitabine in bladder cancer cells.
Isono M; Okubo K; Asano T; Sato A
Sci Rep; 2021 May; 11(1):10181. PubMed ID: 33986399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
